| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 620.9K | $79.68M | - | |
| CEO | 140.4K | $18.02M | - | |
| Other | 52.8K | $6.77M | - | |
| Other | 46.8K | $6.00M | - | |
| Other | 26.9K | $3.45M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2017 | Gano Kyle | Chief Business Development Off | Sale+OE | 24,818 | $71.05 | $1,763,318.90 | -14.5% | |
| Nov 2, 2017 | OBrien Christopher Flint | Chief Medical Officer | Sale+OE | 52,817 | $69.71 | $3,681,640.68 | -35.0% | |
| Oct 2, 2017 | OBrien Christopher Flint | Chief Medical Officer | Sale+OE | 6,925 | $61.04 | $422,702.00 | -12.4% | |
| Sep 6, 2017 | Gano Kyle | Chief Business Development Off | Sale+OE | 20,393 | $60.00 | $1,223,580.00 | -21.8% | |
| Sep 6, 2017 | Lippoldt Darin | Chief Legal Officer | Sale+OE | 100 | $60.00 | $6,000.00 | -0.8% | |
| Sep 6, 2017 | Gano Kyle | Chief Business Development Off | Sale+OE | 4,607 | $60.00 | $276,420.00 | -5.9% | |
| Sep 6, 2017 | Bozigian Haig P. | Chief Development Officer | Sale+OE | 26,250 | $60.00 | $1,575,000.00 | -9.2% | |
| Sep 5, 2017 | OBrien Christopher Flint | Chief Medical Officer | Sale+OE | 52,817 | $57.50 | $3,036,977.50 | -51.9% | |
| Aug 9, 2017 | Lippoldt Darin | Chief Legal Officer | Sale+OE | 5,000 | $55.00 | $275,000.00 | -27.5% | |
| Aug 9, 2017 | Grigoriadis Dimitri E. | Chief Research Officer | Sale+OE | 15,354 | $55.00 | $844,470.00 | -12.5% |